Recardio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.recardio.eu
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
Phase 3
Not yet recruiting
- Conditions
- ST Elevation Myocardial Infarction
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Recardio, Inc.
- Target Recruit Count
- 4100
- Registration Number
- NCT05881382
Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction
Phase 2
Completed
- Conditions
- Acute Myocardial InfarctionAcute Myocardial IschemiaSTEMI - ST Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Recardio, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03486080
- Locations
- 🇳🇱
Maasstad Ziekenhuis, Rotterdam, Netherlands
🇦🇹Clinical department of Cardiology, Graz, Austria
🇵🇱Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi ul. Pomorska 251, Łódź, Poland
© Copyright 2025. All Rights Reserved by MedPath